About LP_LDL

WHAT IS LP_LDL

LP_LDL^® is a naturally-occurring strain of the bacterial species Lactobacillus plantarum, originally isolated from tomatoes. Lactobacilli are common components of the human gut microbiome and have traditionally been used as probiotics. However, what makes LP_LDL different from other Lactobacillus plantarum, is that this particular strain showcases exceptional improvements on the cardiovascular disease risk factors of LDL cholesterol and blood pressure.

Play Video

WHY LP_LDL

Whereas high levels of cholesterol are commonly tackled by approaches that come with multiple undesirable side effects, LP_LDL offers a scientific and naturally founded alternative to support improved cardiovascular health.

LP_LDL was selected using OptiBiotix’s OptiScreen^® proprietary technology platform from a collection of over 4,000 microbial candidates chosen for its excellent:

Play Video

Non-GMO

vegan

QPS bacterium

GMP Certified

High survivability

Easily Added to Manufacturing

FDA Approved

GRAS Approved

Confirmed CVD Biomarkers

How does it work?

LP_LDL is a next generation probiotic, rationally selected and optimised to harness the gut-liver axis for improved cardiovascular health. As well as reducing total and LDL cholesterol, LP_LDL also demonstrated reductions in blood pressure whilst boosting HDL cholesterol.

Lactobacillus plantarum LP_LDL
the probiotic to reduce LDL cholesterol

Promotes bile salt hydrolase (BSH) enzymatic activity, to decreases bile salt reabsorption between the intestine and the liver
This leads to an increase in blood cholesterol uptake by the liver as it is required to synthesise cholesterol into new bile salts to replenish and maintain stable levels
This leads to an increase in blood cholesterol uptake by the liver as it is required to synthesise cholesterol into new bile salts to replenish and maintain stable levels

Scientific
Study Overview

University of Reading

An independent, double blind, randomised, placebo-controlled human study with a tablet containing LP_LDL as the only active was performed by the University of Reading (United Kingdom) in 49 hypercholesterolemic adults. Volunteers consumed a daily dose of 4×109 CFU LP_LDL or a placebo with results based on 12 weeks consumption.

LP_LDL showed to be completely safe and well tolerated.

University of Pavia

An independent, clinical study was carried out at the University of Pavia (Italy) in 40 adults with high normal blood pressure. Volunteers consumed 1 tablet of CholBiome_BP per day (containing 4×109 CFU LP_LDL) with results based on 12 week’s consumption Vs baseline (pre-intervention) levels.